Skip to main content
. 2018 May 21;58(5):715–723. doi: 10.1111/head.13316

Table 3.

Summary of Adverse Events – 12‐week Follow‐Up

Placebo (N = 44) Erenumab 140 mg IV (N = 44)
Adverse events, n (%)
Any 14 (32) 12 (27)
Serious 1 (2) 0 (0)
Fatal 0 (0) 0 (0)

Safety analyses set; all patients randomized who received at least 1 dose of study drug.